Y-27632 dihydrochloride: Selective ROCK Inhibitor for Cell Signaling and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a potent and selective ROCK1/2 inhibitor with an IC₅₀ of ~140 nM for ROCK1 and Ki of 300 nM for ROCK2, displaying >200-fold selectivity over other kinases (APExBIO product page). The compound disrupts Rho-mediated stress fiber formation and modulates the cell cycle, making it essential in studies of cytoskeletal dynamics, stem cell viability, and tumor invasion. In vitro and in vivo studies confirm its efficacy in reducing prostatic smooth muscle cell proliferation and suppressing metastasis (Ren et al., 2025). Its robust solubility in DMSO, ethanol, and water, combined with reliable storage parameters, supports reproducible experimental workflows. Y-27632 serves as a benchmark tool for dissecting Rho/ROCK pathway mechanisms in cancer, virology, and developmental biology.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases that mediate downstream effects of the small GTPase RhoA. These kinases regulate actin cytoskeleton organization, cell contraction, migration, and proliferation. Aberrant Rho/ROCK signaling is implicated in tumor progression, fibrosis, and inflammatory responses (Ren et al., 2025). In canine and human models, disruption of this pathway alters cell adhesion, tight junction integrity, and tissue homeostasis. Y-27632 dihydrochloride enables selective inhibition of ROCK1/2, allowing researchers to probe the functional consequences of Rho/ROCK modulation without significant off-target effects (APExBIO).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride targets the catalytic domains of ROCK1 and ROCK2. Upon binding, it prevents the phosphorylation of downstream substrates such as myosin light chain 2 (MLC2), LIM kinase, and cofilin. Inhibition results in decreased actomyosin contractility and reduced formation of cellular stress fibers. This compound does not significantly inhibit kinases like PKC, PKA, MLCK, or PAK at concentrations <30 μM, confirming its high selectivity (APExBIO). In models of viral infection, Y-27632 blocks RhoA/ROCK1-mediated MLC2 phosphorylation, preserving tight junctions and limiting pathogen entry (Ren et al., 2025).

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of approximately 140 nM and ROCK2 with a Ki of 300 nM (APExBIO, product page).
• Displays >200-fold selectivity over PKC, PKA, MLCK, and PAK at <30 μM (APExBIO).
• Suppresses RhoA/ROCK1-mediated phosphorylation of MLC2, preserving tight junctions and reducing viral entry in canine WRD cells (Ren et al., 2025, DOI).
• Reduces prostatic smooth muscle cell proliferation in vitro in a concentration-dependent manner (APExBIO, product page).
• Diminishes tumor invasion and metastasis in mouse models (Ren et al., 2025, DOI).
• Solubility: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water at 20–25°C; enhanced by warming or ultrasonic bath (APExBIO).
• Stock solutions stable at ≤-20°C for several months; solid supplied desiccated at 4°C or below (APExBIO).

This article extends the scope of previous overviews by emphasizing molecular mechanisms and experimental parameters for advanced users. It also clarifies the selectivity profile beyond organoid-focused applications and updates translational guidance relative to earlier reviews on cancer and tissue engineering.

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is used in:

• Cytoskeletal research: Inhibits stress fiber formation and focal adhesion assembly.
• Stem cell biology: Enhances viability during iPSC and hESC passaging.
• Cancer biology: Suppresses tumor cell invasion and metastasis in preclinical models.
• Virology: Prevents RhoA/ROCK1-mediated tight junction loss, reducing viral spread.
• Cell proliferation assays: Modulates cell cycle progression and cytokinesis.

Common Pitfalls or Misconceptions

• Y-27632 dihydrochloride does not inhibit all Rho pathway effectors; it is selective for ROCK1/2.
• It does not block upstream GTPase activity (e.g., RhoA activation).
• Prolonged exposure (>72 h) in certain cell types may cause off-target effects; always optimize dosing.
• Not intended for clinical or veterinary therapeutic use—research only.
• Solubility and stability may be compromised by repeated freeze-thaw cycles.

For advanced insights into neural differentiation and non-cancer applications, see this neural research primer, which this article updates with new selectivity data and workflow guidance.

Workflow Integration & Parameters

Y-27632 dihydrochloride is typically dissolved at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. Solubilization is enhanced by warming to 37°C or using an ultrasonic bath. Working concentrations range from 1–50 μM, depending on cell type and application. For storage, stock solutions should be kept below -20°C, and the solid form must be desiccated at 4°C or lower. Avoid repeated freeze-thaw cycles to preserve activity. In cell-based assays, add Y-27632 dihydrochloride immediately prior to use and filter-sterilize if necessary.

For step-by-step protocols and experimental design, refer to the A3008 product page from APExBIO.

Conclusion & Outlook

Y-27632 dihydrochloride has become an essential research tool for dissecting the Rho/ROCK signaling pathway. Its high selectivity and potency enable precise modulation of cytoskeletal and cell cycle functions. Applications range from stem cell maintenance to cancer metastasis research and advanced virology. Ongoing studies continue to expand its utility, particularly in translational models and disease mechanism elucidation. For reliable supply and technical support, APExBIO provides validated Y-27632 dihydrochloride under catalog number A3008. For expanded applications and the latest mechanistic updates, see recent advanced reviews (here).